217 related articles for article (PubMed ID: 29351636)
1. Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants.
Wu P; Escobar GJ; Gebretsadik T; Carroll KN; Li SX; Walsh EM; Mitchel EF; Sloan C; Dupont WD; Yu C; Horner JR; Hartert TV
Am J Epidemiol; 2018 Jul; 187(7):1490-1500. PubMed ID: 29351636
[TBL] [Abstract][Full Text] [Related]
2. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
Kong AM; Winer IH; Zimmerman NM; Diakun D; Bloomfield A; Gonzales T; Fergie J; Goldstein M; Krilov LR
Am J Perinatol; 2023 Oct; 40(14):1529-1536. PubMed ID: 34704241
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma.
Carroll KN; Gebretsadik T; Escobar GJ; Wu P; Li SX; Walsh EM; Mitchel E; Sloan CD; Dupont WD; Hartert TV
J Allergy Clin Immunol; 2017 Jan; 139(1):66-71.e3. PubMed ID: 27212083
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: a retrospective cohort study.
Flaherman V; Li S; Ragins A; Masaquel A; Kipnis P; Escobar GJ
Clin Ther; 2010 Dec; 32(13):2220-9. PubMed ID: 21316538
[TBL] [Abstract][Full Text] [Related]
6. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
Prais D; Schonfeld T; Amir J;
Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus infection and immunoprophylaxis for selected high-risk children in Central Australia.
Bolisetty S; Wheaton G; Chang AB
Aust J Rural Health; 2005 Oct; 13(5):265-70. PubMed ID: 16171499
[TBL] [Abstract][Full Text] [Related]
8. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
10. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
Winterstein AG; Knox CA; Kubilis P; Hampp C
JAMA Pediatr; 2013 Dec; 167(12):1118-24. PubMed ID: 24126903
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.
Stockman LJ; Curns AT; Anderson LJ; Fischer-Langley G
Pediatr Infect Dis J; 2012 Jan; 31(1):5-9. PubMed ID: 21817948
[TBL] [Abstract][Full Text] [Related]
12. Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines.
Choi Y; Meissner HC; Hampp C; Park H; Winterstein AG
Eur J Pediatr; 2022 Feb; 181(2):841-845. PubMed ID: 34365543
[TBL] [Abstract][Full Text] [Related]
13. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
Staebler S; Blake S
Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
Winterstein AG; Eworuke E; Xu D; Schuler P
Pediatr Pulmonol; 2013 Sep; 48(9):874-84. PubMed ID: 23139089
[TBL] [Abstract][Full Text] [Related]
15. Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.
Winterstein AG; Choi Y; Meissner HC
JAMA Pediatr; 2018 Feb; 172(2):154-160. PubMed ID: 29204660
[TBL] [Abstract][Full Text] [Related]
16. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
[TBL] [Abstract][Full Text] [Related]
17. Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations.
Bennett MV; McLaurin K; Ambrose C; Lee HC
PLoS One; 2018; 13(10):e0205399. PubMed ID: 30379957
[TBL] [Abstract][Full Text] [Related]
18. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
Goldstein M; Krilov LR; Fergie J; McLaurin KK; Wade SW; Diakun D; Lenhart GM; Bloomfield A; Kong AM
Am J Perinatol; 2018 Dec; 35(14):1433-1442. PubMed ID: 29920638
[TBL] [Abstract][Full Text] [Related]
19. Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.
Doucette A; Jiang X; Fryzek J; Coalson J; McLaurin K; Ambrose CS
PLoS One; 2016; 11(4):e0152208. PubMed ID: 27050095
[TBL] [Abstract][Full Text] [Related]
20. Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study.
Agüera M; Soler-Garcia A; Alejandre C; Moussalam-Merino S; Sala-Castellví P; Pons G; Penela-Sánchez D; González-Grado C; Alsina-Rosell J; Climent C; Esteva C; Fortuny C; de-Sevilla MF; García-García JJ; Brotons P; Balaguer A; Estrada J; Jordan I; Muñoz-Almagro C; Launes C
Pediatr Allergy Immunol; 2024 Jun; 35(6):e14175. PubMed ID: 38899631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
